AVTX: Advancing anti-IL-1 beta therapy to phase III for HS, expanding indications, and securing strong financial support
A clinical-stage biotech is advancing its potent anti-IL-1 beta antibody, abdakibart, into phase III for HS after strong phase II results and positive physician feedback. Expansion plans include a long-acting version and new indications in dermatology and rheumatology, with robust financial backing…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.